Eleven clinical Klebsiella pneumoniae fluoroquinolone-resistant isolates were tested to access the potential of adjuvant therapies to reduce antimicrobial resistance using fixed concentrations of the chemosensitizers chlorpromazine (CPZ), thioridazine (TZ), phenylalanine-arginine-β-naphthylamide (PAβN), and 1-(1-naphthylmethyl)-piperazine-(NMP) with varying concentrations of antimicrobial agents nalidixic acid (NAL), ciprofloxacin (CIP), moxifloxacin (MXF), tetracycline (TET), and chloramphenicol (CHL). Ethidium bromide dye was used together with the chemosensitizers to investigate permeabilization effects. NMP was assessed for its capacity to reduce the mass of biofilm alone and in combination with CIP and MXF. Of the selected chemosensitizers, NMP exhibited the greatest capacity to reverse resistance and inhibit efflux, based on the concentrations tested. Susceptibility to antimicrobial agents including (fluoro)quinolones, TET, and CHL were found to be increased in the presence of NMP, in a concentration-dependent manner. PAβN also demonstrated similar effects when combined with the chemosensitizers tested. In the case of half of the isolates studied, NMP alone reduced preformed biofilm biomass. Combinations of latter along with CIP or MXF were also found to reduce the mass of preformed biofilm, in the case of only some of the bacterial isolates. The capacity of NMP to reduce antimicrobial resistance could be of relevance as a strategy to limit bacterial colonization on abiotic surfaces.
Get full access to this article
View all access options for this article.
References
1.
O'NeillJ.2014. The review on antimicrobial resistance: tackling a crisis for the health and wealth of nations. Available at: https://amr-review.org/Publications.html (accessed July3, 2018).
2.
World Health Organization. 2014. Antimicrobial Resistance: Global Report on Surveillance. World Health Organization, Geneva.
3.
MeekR.W., VyasH., and L.J.V. Piddock. 2015. Nonmedical uses of antibiotics: time to restrict their use? PLoS Biol., 13:1–11.
4.
MichaelC.A., Dominey-HowesD., and LabbateM.. 2014. The antimicrobial resistance crisis: causes, consequences, and management. Front. Public Health, 2:145.
5.
Centres for Disease Control and Prevention. 2013. Antimicrobial Resistance Threaths in the United States. Centres for Disease Control and Prevention, Atlanta, GA.
6.
BaratiA., GhaderpourA., ChewL.L., BongC.W., ThongK.L., ChongV.C., ChaiL.C.. 2016. Isolation and characterization of aquatic-borne Klebsiella pneumoniae from tropical estuaries in Malaysia. Int. J. Environ. Res. Public Health, 13:426.
7.
KimS.-H., WeiC.-I., TzouY.-M., and AnH.. 2005. Multidrug-resistant Klebsiella pneumoniae isolated from farm environments and retail products in Oklahoma. J. Food Prot., 68:2022–2029.
8.
LeeG.C., and BurgessD.S.. 2012. Treatment of Klebsiella pneumoniae carbapenemase (KPC) infections: a review of published case series and case reports. Ann. Clin. Microbiol. Antimicrob., 11:32.
9.
PodschunR., and UllmannU.. 1998. Klebsiella spp. as nosocomial pathogens: epidemiology, taxonomy, methods, and pathogenicity factors. Clin. Microbiol. Rev., 11:589–603.
10.
SchwaberM.J., Klarfeld-LidjiS., Navon-VeneziaS., SchwartzD., LeavittA., and CarmeliY.. 2008. Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality. Antimicrob. Agents Chemother., 52:1028–1033.
11.
AranaD.M., RubioM., and AlósJ.-I.. 2017. Evolution of antibiotic multiresistance in Escherichia coli and Klebsiella pneumoniae isolates from urinary tract infections: a 12-year analysis (2003–2014). Enferm. Infecc. Microbiol. Clin., 35:293–298.
12.
SinghaiM., MalikA., ShahidM., MalikM.A., and GoyalR.. 2012. A study on device-related infections with special reference to biofilm production and antibiotic resistance. J. Glob. Infect. Dis., 4:193–198.
13.
VuottoC., LongoF., BaliceM., DonelliG., and VaraldoP.. 2014. Antibiotic resistance related to biofilm formation in Klebsiella pneumoniae. Pathogens, 3:743–758.
NeyfakhA.A., BidnenkoV.E., and ChenL.B.. 1991. Efflux-mediated multidrug resistance in Bacillus subtilis: similarities and dissimilarities with the mammalian system. Proc. Natl. Acad. Sci. U. S. A., 88:4781–4785.
16.
LeeM.D., GalazzoJ.L., StaleyA.L., LeeJ.C., WarrenM.S., FuernkranzH., ChamberlandS., LomovskayaO., and MillerG.H.. 2001. Microbial fermentation-derived inhibitors of efflux-pump-mediated drug resistance. Farmaco, 56:81–85.
17.
OppermanT.J., KwasnyS.M., KimH.-S., NguyenS.T., HouseweartC., D'SouzaS., WalkerG.C., PeetN.P., NikaidoH., and BowlinT.L.. 2014. Characterization of a novel pyranopyridine inhibitor of the AcrAB efflux pump of Escherichia coli. Antimicrob. Agents Chemother., 58:722–733.
18.
VargiuA.V., RuggeroneP., OppermanT.J., NguyenS.T., and NikaidoH.. 2014. Molecular mechanism of MBX2319 inhibition of Escherichia coli AcrB multidrug efflux pump and comparison with other inhibitors. Antimicrob. Agents Chemother., 58:6224–6234.
19.
BohnertJ.A., SchusterS., and KernW.V.2013. Pimozide inhibits the AcrAB-TolC efflux pump in Escherichia coli. Open Microbiol. J., 7:83–86.
20.
BohnertJ.A., and KernW.V.2005. Selected arylpiperazines are capable of reversing multidrug resistance in Escherichia coli overexpressing RND efflux pumps. Antimicrob. Agents Chemother., 49:849–852.
21.
SchumacherA., SteinkeP., BohnertJ.A., AkovaM., JonasD., and KernW.V.2006. Effect of 1-(1-naphthylmethyl)-piperazine, a novel putative efflux pump inhibitor, on antimicrobial drug susceptibility in clinical isolates of Enterobacteriaceae other than Escherichia coli. J. Antimicrob. Chemother., 57:344–348.
22.
KernW.V., SteinkeP., SchumacherA., SchusterS., von BaumH., and BohnertJ.A.. 2006. Effect of 1-(1-naphthylmethyl)-piperazine, a novel putative efflux pump inhibitor, on antimicrobial drug susceptibility in clinical isolates of Escherichia coli. J. Antimicrob. Chemother., 57:339–343.
23.
Ospina BarreroM.A., PietralongaP.A.G., SchwarzD.G.G., Silva JuniorA., PaulaS.O., and M.A.S. Moreira. 2014. Effect of the inhibitors phenylalanine arginyl ß-naphthylamide (PAßN) and 1-(1-naphthylmethyl)-piperazine (NMP) on expression of genes in multidrug efflux systems of Escherichia coli isolates from bovine mastitis. Res. Vet. Sci., 97:176–181.
24.
LamersR.P., CavallariJ.F., BurrowsL.L., NikaidoH., and PagesJ.. 2013. The efflux inhibitor phenylalanine-arginine beta-naphthylamide (PAβN) permeabilizes the outer membrane of gram-negative bacteria. PLoS One, 8:e60666.
25.
OppermanT.J., and NguyenS.T.. 2015. Recent advances toward a molecular mechanism of efflux pump inhibition. Front. Microbiol., 6:421.
26.
AnesJ., HurleyD., MartinsM., and FanningS.. 2017. Exploring the genome and phenotype of multi-drug resistant Klebsiella pneumoniae of clinical origin. Front. Microbiol., 8:1913.
27.
PaixãoL., RodriguesL., CoutoI., MartinsM., FernandesP., de CarvalhoC.C., MonteiroG.A., SansonettyF., AmaralL., and ViveirosM.. 2009. Fluorometric determination of ethidium bromide efflux kinetics in Escherichia coli. J. Biol. Eng., 3:18.
28.
AmaralL., and MolnarJ.. 2012. Why and how thioridazine in combination with antibiotics to which the infective strain is resistant will cure totally drug-resistant tuberculosis. Expert Rev. Anti. Infect. Ther., 10:869–873.
29.
SpindlerE.C., HaleJ.D.F., GiddingsT.H., HancockR.E.W., and GillR.T.. 2011. Deciphering the mode of action of the synthetic antimicrobial peptide Bac8c. Antimicrob. Agents Chemother., 55:1706–1716.
30.
YuZ., CaiY., QinW., LinJ., and QiuJ.. 2015. Polymyxin E induces rapid Paenibacillus polymyxa death by damaging cell membrane while Ca2+ can protect cells from damage. PLoS One, 10:e0135198.
31.
Ohene-AgyeiT., MowlaR., RahmanT., and VenterH.. 2014. Phytochemicals increase the antibacterial activity of antibiotics by acting on a drug efflux pump. Microbiologyopen, 3:885–896.
32.
ChenL., MathemaB., ChavdaK.D., DeLeoF.R., BonomoR.A., and KreiswirthB.N.. 2014. Carbapenemase-producing Klebsiella pneumoniae: molecular and genetic decoding. Trends Microbiol., 22:686–696.
33.
HoltK.E., WertheimH., ZadoksR.N., BakerS., WhitehouseC.A., DanceD., JenneyA., ConnorT.R., HsuL.Y., SeverinJ., BrisseS., CaoH., WilkschJ., GorrieC., SchultzM.B., EdwardsD.J., NguyenK.V., NguyenT.V., DaoT.T., MensinkM., MinhV.L., NhuN.T., SchultszC., KuntamanK., NewtonP.N., MooreC.E., StrugnellR.A., and ThomsonN.R.. 2015. Genomic analysis of diversity, population structure, virulence, and antimicrobial resistance in Klebsiella pneumoniae, an urgent threat to public health. Proc. Natl. Acad. Sci. U. S. A., 112:E3574–E3581.
34.
Bialek-DavenetS., LavigneJ.-P., GuyotK., MayerN., TournebizeR., BrisseS., Leflon-GuiboutV., and Nicolas-ChanoineM.H.. 2015. Differential contribution of AcrAB and OqxAB efflux pumps to multidrug resistance and virulence in Klebsiella pneumoniae. J. Antimicrob. Chemother., 70:81–88.
35.
RedgraveL.S., SuttonS.B., WebberM.A., and PiddockL.J. V. 2014. Fluoroquinolone resistance: mechanisms, impact on bacteria, and role in evolutionary success. Trends Microbiol., 22:438–445.
36.
MoonD.C., SeolS.Y., GurungM., JinJ.S., ChoiC.H., KimJ., LeeY.C., ChoD.T., and LeeJ.C.. 2010. Emergence of a new mutation and its accumulation in the topoisomerase IV gene confers high levels of resistance to fluoroquinolones in Escherichia coli isolates. Int. J. Antimicrob. Agents, 35:76–79.
37.
PakzadI., Zayyen KarinM., TaherikalaniM., BoustanshenasM., and LariA.R.. 2013. Contribution of AcrAB efflux pump to ciprofloxacin resistance in Klebsiella pneumoniae isolated from burn patients. GMS Hyg. Infect. Control, 8:Doc15.
38.
OgawaW., OnishiM., NiR., TsuchiyaT., and KurodaT.. 2012. Functional study of the novel multidrug efflux pump KexD from Klebsiella pneumoniae. Gene, 498:177–182.
39.
PerezF., RudinS.D., MarshallS.H., CoakleyP., ChenL., KreiswirthB.N., RatherP.N., HujerA.M., ToltzisP., van DuinD., PatersonD.L., and BonomoR.A.. 2013. OqxAB, a quinolone and olaquindox efflux pump, is widely distributed among multidrug-resistant Klebsiella pneumoniae isolates of human origin. Antimicrob. Agents Chemother., 57:4602–4603.
40.
XiongX., BromleyE.H.C., OelschlaegerP., WoolfsonD.N., and SpencerJ.. 2011. Structural insights into quinolone antibiotic resistance mediated by pentapeptide repeat proteins: conserved surface loops direct the activity of a Qnr protein from a gram-negative bacterium. Nucleic Acids Res., 39:3917–3927.
41.
HendricksO., ButterworthT.S., and KristiansenJ.E.. 2003. The in-vitro antimicrobial effect of non-antibiotics and putative inhibitors of efflux pumps on Pseudomonas aeruginosa and Staphylococcus aureus. Int. J. Antimicrob. Agents, 22:262–264.
42.
KristiansenJ.E., ThomsenV.F., MartinsA., ViveirosM., and AmaralL.. 2010. Non-antibiotics reverse resistance of bacteria to antibiotics. In Vivo, 24:751–754.
43.
MarchettiM.L., ErrecaldeJ., and MestorinoN.. 2012. Effect of 1-(1-naphthylmethyl)-piperazine on antimicrobial agent susceptibility in multidrug-resistant isogenic and veterinary Escherichia coli field strains. J. Med. Microbiol., 61:786–792.
44.
BaileyA.M., PaulsenI.T., and PiddockL.J. V. 2008. RamA confers multidrug resistance in Salmonella enterica via increased expression of acrB, which is inhibited by chlorpromazine. Antimicrob. Agents Chemother., 52:3604–3611.
45.
DasguptaA., MukherjeeS., ChakiS., DastidarS.G., HendricksO., ChristensenJ.B., KristiansenJ.E., and AmaralL.. 2010. Thioridazine protects the mouse from a virulent infection by Salmonella enterica serovar Typhimurium 74. Int. J. Antimicrob. Agents, 35:174–176.
46.
PannekS., HigginsP.G., SteinkeP., JonasD., AkovaM., BohnertJ.A., SeifertH., and KernW.V.. 2006. Multidrug efflux inhibition in Acinetobacter baumannii: comparison between 1-(1-naphthylmethyl)-piperazine and phenyl-arginine-β-naphthylamide. J. Antimicrob. Chemother., 57:970–974.
47.
BinaX.R., PhilippartJ.A., and BinaJ.E.. 2008. Effect of the efflux inhibitors 1-(1-naphthylmethyl)-piperazine and phenyl-arginine-β-naphthylamide on antimicrobial susceptibility and virulence factor production in Vibrio cholerae. J. Antimicrob. Chemother., 63:103–108.
48.
HeF., FuY., ChenQ., RuanZ., HuaX., ZhouH., and YuY.. 2015. Tigecycline susceptibility and the role of efflux pumps in tigecycline resistance in KPC-producing Klebsiella pneumoniae. PLoS One, 10:e0119064.
49.
ChopraI., and RobertsM.. 2001. Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol. Mol. Biol. Rev., 65:232–260; second page, table of contents.
50.
WilsonD.N.2014. Ribosome-targeting antibiotics and mechanisms of bacterial resistance. Nat. Rev. Microbiol., 12:35–48.
51.
RobertsM.C., and SchwarzS.. 2009. Tetracycline and chloramphenicol resistance mechanisms. In: MayersD.L. (ed), Antimicrobial drug resistance. Humana Press, Totowa, NJ, pp. 183–193.
52.
LamsonN.G., CusimanoG., SuriK., ZhangA., and WhiteheadK.A.. 2016. The pH of piperazine derivative solutions predicts their utility as transepithelial permeation enhancers. Mol. Pharm., 13:578–585.
53.
LebeauxD., ChauhanA., LétofféS., FischerF., de ReuseH., BeloinC., and GhigoJ.M.. 2014. pH-Mediated potentiation of aminoglycosides kills bacterial persisters and eradicates in vivo biofilms. J. Infect. Dis., 210:1357–1366.
54.
LawlerA.J., RicciV., BusbyS.J.W., and PiddockL.J. V. 2013. Genetic inactivation of acrAB or inhibition of efflux induces expression of ramA. J. Antimicrob. Chemother., 68:1551–1557.
55.
SchusterS., KohlerS., BuckA., DambacherC., KönigA., BohnertJ.A., and KernW.V.. 2014. Random mutagenesis of the multidrug transporter AcrB from Escherichia coli for identification of putative target residues of efflux pump inhibitors. Antimicrob. Agents Chemother., 58:6870–6878.
56.
MowlaR., WangY., MaS., and VenterH.. 2018. Kinetic analysis of the inhibition of the drug efflux protein AcrB using surface plasmon resonance. Biochim. Biophys. Acta, 1860:878–886.
57.
LomovskayaO., WarrenM.S., LeeA., GalazzoJ., FronkoR., LeeM., BlaisJ., ChoD., ChamberlandS., RenauT., LegerR., HeckerS., WatkinsW., HoshinoK., IshidaH., and LeeV.J.. 2001. Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy. Antimicrob. Agents Chemother., 45:105–116.
58.
KvistM., HancockV., and KlemmP.. 2008. Inactivation of efflux pumps abolishes bacterial biofilm formation. Appl. Environ. Microbiol., 74:7376–7382.
59.
StewartP.S.1996. Theoretical aspects of antibiotic diffusion into microbial biofilms. Antimicrob. Agents Chemother., 40:2517–2522.
60.
MahT.F., and O'TooleG.A.. 2001. Mechanisms of biofilm resistance to antimicrobial agents. Trends Microbiol., 9:34–39.
61.
BeloinC., ValleJ., Latour-LambertP., FaureP., KzreminskiM., BalestrinoD., HaagensenJ.A., MolinS., PrensierG., ArbeilleB., and GhigoJ.M.. 2003. Global impact of mature biofilm lifestyle on Escherichia coli K-12 gene expression. Mol. Microbiol., 51:659–674.
62.
BollaJ.-M., Alibert-FrancoS., HandzlikJ., ChevalierJ., MahamoudA., BoyerG., Kieć-KononowiczK., and PagèsJ.M.. 2011. Strategies for bypassing the membrane barrier in multidrug resistant Gram-negative bacteria. FEBS Lett., 585:1682–1690.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
